Saúde Pública®Edições Especiais Saúde Pública®Mundo Médico®Edições especiais Mundo Médico®Mundo Farmacêutico®Informação SIDA®HematOncologia®Jornal Pré-CongressoJornal do CongressoJornal Diário do CongressoSaúde em Dia®Outros Projectos
Encontre-nos no Facebook
Pretendemos promover e divulgar a informação na área da Saúde. A reprodução total ou parcial dos textos e fotografias é possível, desde que referenciada a sua origem (JAS Farma®), o link (www.jasfarma.com) e com a autorização expressa da Direcção.
Notícia
1st World Congress on Debates and Consensus in Bone, Muscle and Joint Diseases (BMJD)
A primeira edição do World Congress on Debates and Consensus in Bone, Muscle and Joint Diseases (BMJD) irá realizar-se em Espanha, na cidade de Barcelona, entre os dias 19 e 22 de Janeiro de 2012. O evento é dirigido especialmente a endocrinologistas, reumatologistas, ginecologistas, médicos internos, radiologistas, especialistas em Reabilitação, profissionais da área da saúde pública, enfermeiros e representantes da indústria.
Partilhar e comparar experiências
De acordo com Claus Christiansen, Presidente do Congresso, após a intervenção de cada orador está previsto um amplo período de tempo dedicado à discussão dos temas abordados, onde os participantes poderão debater questões em aberto com alguns dos principais especialistas mundiais nas suas áreas. O objectivo é facilitar um debate efectivo sobre dilemas clínicos e terapêuticos. «A congress that focuses on clinical controversies is an entirely new concept» salienta Claus Christiansen.
Temas de Debates:
Estrogen and Estrogen-like Molecules – do the benefits outweigh the risks?
Do we need to stimulate bone formation to obtain an anabolic condition?
What is the controversy regarding the possible intervention strategy for postmenopausal OP?
Do we really understand the PTH mode of action?
Can anti-resorptive treatments inhibit bone resorbtion without secondary effects on bone formation?
Current and future antibody interventions in osteoporosis (DMAB and Anti-sclerositin)
Does Oral Calcitonin Provide a Positive Calcium Balance?
Should we treat women with low BMD who are under 65 years of age, and how?
Do we have effective mode of treatment or prevention for OA?
Are there common disease initiators and drivers in RA and OA? Is bone a primary or secondary part of the pathogenesis of the disease? Do we need to target bone remodeling for optimal clinical benefit in cartilage diseases?
Can effective treatment for OP or RA also be effective in a selected patient population with OA? Clashing views or consensus? What type of effect can we expect by using the following treatments in other fields?
Can we devise an optimal treatment for OA-related pain? Should pain be controlled centrally, peripherally, or both?
Is oral calcitonin a possible dual action intervention strategy for osteoarthritis
Does glucosamine have any role in OA?
Imaging, biochemical biomarkers, or both: Can they provide information on the progression or remission of OP, OA and RA?
With so many choices of treatment in RA, and no head-to-head comparisons, how do we select the optimal treatment for the right patient?
Can Bisphosphonates act as Anti-Cancer Drugs?
Anti-Sclerostin antibody - an anabolic agent for bone metastasis?
Is muscle wasting the cause or the consequence of frailty? Are there positive secondary effects of preventing sarcopenia?
Secretariado do Congresso:
GL events | Package Organisation
10 quai Charles de Gaulle
69463 Lyon Cedex 06
France
Tel. +33 4 78 176 176
Fax. +33 4 78 176 257
Email: [email protected]
CongressMed Ltd.
20 Lincoln Street
Rubinstein Bld. / Floor 13
Tel Aviv 67134
Israel
Tel. +972 73 706950
Fax. +972 73 706951
Email: [email protected]
Website do Congresso: http://www.congressmed.com/bmjd
Partilhar e comparar experiências
De acordo com Claus Christiansen, Presidente do Congresso, após a intervenção de cada orador está previsto um amplo período de tempo dedicado à discussão dos temas abordados, onde os participantes poderão debater questões em aberto com alguns dos principais especialistas mundiais nas suas áreas. O objectivo é facilitar um debate efectivo sobre dilemas clínicos e terapêuticos. «A congress that focuses on clinical controversies is an entirely new concept» salienta Claus Christiansen.
Temas de Debates:
Estrogen and Estrogen-like Molecules – do the benefits outweigh the risks?
Do we need to stimulate bone formation to obtain an anabolic condition?
What is the controversy regarding the possible intervention strategy for postmenopausal OP?
Do we really understand the PTH mode of action?
Can anti-resorptive treatments inhibit bone resorbtion without secondary effects on bone formation?
Current and future antibody interventions in osteoporosis (DMAB and Anti-sclerositin)
Does Oral Calcitonin Provide a Positive Calcium Balance?
Should we treat women with low BMD who are under 65 years of age, and how?
Do we have effective mode of treatment or prevention for OA?
Are there common disease initiators and drivers in RA and OA? Is bone a primary or secondary part of the pathogenesis of the disease? Do we need to target bone remodeling for optimal clinical benefit in cartilage diseases?
Can effective treatment for OP or RA also be effective in a selected patient population with OA? Clashing views or consensus? What type of effect can we expect by using the following treatments in other fields?
Can we devise an optimal treatment for OA-related pain? Should pain be controlled centrally, peripherally, or both?
Is oral calcitonin a possible dual action intervention strategy for osteoarthritis
Does glucosamine have any role in OA?
Imaging, biochemical biomarkers, or both: Can they provide information on the progression or remission of OP, OA and RA?
With so many choices of treatment in RA, and no head-to-head comparisons, how do we select the optimal treatment for the right patient?
Can Bisphosphonates act as Anti-Cancer Drugs?
Anti-Sclerostin antibody - an anabolic agent for bone metastasis?
Is muscle wasting the cause or the consequence of frailty? Are there positive secondary effects of preventing sarcopenia?
Secretariado do Congresso:
GL events | Package Organisation
10 quai Charles de Gaulle
69463 Lyon Cedex 06
France
Tel. +33 4 78 176 176
Fax. +33 4 78 176 257
Email: [email protected]
CongressMed Ltd.
20 Lincoln Street
Rubinstein Bld. / Floor 13
Tel Aviv 67134
Israel
Tel. +972 73 706950
Fax. +972 73 706951
Email: [email protected]
Website do Congresso: http://www.congressmed.com/bmjd
Copyright © 2006 JAS Farma®
Pretendemos promover e divulgar a informação na área da Saúde. A reprodução total ou parcial dos textos e fotografias é possível, desde que referenciada a sua origem (JAS Farma®) e com a autorização expressa da Direcção.